Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Systech International Adds Distinguished Members to its Board

Published: Tuesday, February 12, 2013
Last Updated: Tuesday, February 12, 2013
Bookmark and Share
Systech International announces the addition of John Bailye and Michael Fawkes to its Board of Directors.

Robert DeJean, President and CEO, Systech International said: “We are delighted to welcome new members to our Board, John Bailye and Michael Fawkes, who bring a vast amount of industry experience and business acumen upon which Systech will draw as we continue to grow.”

John Bailye is a globally accomplished entrepreneur with a resume that runs the gamut from start-ups to proven operational management and strategic leadership in mid to large sized companies. John’s successes reflect a passion for focusing on his customers, both as a source of product direction and, as the ultimate arbiter of his companies’ success.

In a career covering strategic consulting services; leading edge global technology development and deployment and; of late, specialty pharmaceuticals, he has consistently demonstrated his ability to build great management teams and deliver outstanding returns to shareholders. In John’s penultimate role, he guided, developed and grew Dendrite International from a two-person startup company to a complex global business entity over a period of 20 years. Dendrite had $750 million in market capitalized value, over $450 million in annual sales with high profitability, and more than 3000 employees in over 25 countries.

John Bailye said: “I am honored to join Systech’s Board of Directors. As a market leader with innovative technology in a rapidly growing market and new senior management additions, Systech is poised for significant growth. The company is thriving and I’m eager to help shape the organizational direction over the coming months and years.”

Michael Fawkes brings more than 30 years of experience to the Systech Board. Currently he serves as an Independent Director for Saba Software, a NASDAQ listed company, as well as several private technology companies.

From February 2008 through January 2012, Michael served as an Operating Partner with Vantage Point Capital Partners, a leading global investor in energy innovation and efficiency, information technology and healthcare.

Prior to joining Vantage Point Capital Partners, Michael spent 29 years at Hewlett-Packard Company, a leading global provider of products, technologies, software, solutions and services to individuals and businesses, serving in various executive roles in operations and finance, including Senior Vice President of Operations for HP’s Imaging and Printing business. Prior to joining HP, Michael was a CPA with Arthur Andersen. Michael holds a B.B.A. and a M.A. in Finance from the University of Iowa.

Michael Fawkes said: “Systech is positioned very well to make a critical contribution to patient safety as it helps its customers combat counterfeiting in the Pharmaceutical market. Additionally, Systech has a tremendous opportunity to advance its offering to other markets. I am thrilled to have the opportunity to work with Systech as its scales for the future.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos